Hyundai Pharmaceutical Co., Ltd. (004310.KS) Stock
Hyundai Pharmaceutical Co., Ltd.

Company profile
Hyundai Pharmaceutical reported revenue of 191.79 billion KRW for fiscal year 2025, up 9.1% from fiscal year 2024. In Q1 2026 (the quarter ended February 28, 2026) revenue was 46.45 billion KRW, up 7.8% from a year before. In Q1 2026 it reported net income of 420.00 million KRW, against a net loss of 985.27 million KRW a year earlier. Our analysis of its filings shows revenue growing from 180.76 billion KRW in fiscal year 2023 to 191.79 billion KRW in fiscal year 2025, 3.0% a year on average.
What stands out
- Its net profit margin over the last four reported quarters was 1.3%, against a median of -58.0% for 6 listed companies of similar size in its industry.
- It returned to a profit in fiscal year 2025, 2.52 billion KRW, after a net loss of 574.89 million KRW in fiscal year 2024.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended November 30, 2025.
About Hyundai Pharmaceutical Co., Ltd.
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. Hyundai Pharmaceutical Co., Ltd. was founded in 1965 and is headquartered in Seoul, South Korea.
Largest shareholders
- Shinpoong Pharmaceutical Co.,Ltd7.21%
Share of the company, as of September 25, 2026
Leadership
- Sang-Jun Lee — President, 49
How much revenue does Hyundai Pharmaceutical make?
Hyundai Pharmaceutical reported 191.79 billion KRW in revenue for fiscal year 2025, up 9.1% from 175.74 billion KRW in fiscal year 2024. In Q1 2026 revenue was 46.45 billion KRW.
What companies are similar to Hyundai Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Inventage Lab, Inc. (389470.KQ), Union Korea Pharm Co., Ltd. (080720.KQ), Samjin Pharmaceuticals Co., Ltd. (005500.KS), Huons Co., Ltd. (243070.KQ).
How does Hyundai Pharmaceutical's profit margin compare with similar companies?
Net profit margin over the last four reported quarters: Hyundai Pharmaceutical, 1.3%; Inventage Lab, Inc. (389470.KQ), -127.0%; Union Korea Pharm Co., Ltd. (080720.KQ), -95.5%; Samjin Pharmaceuticals Co., Ltd. (005500.KS), 8.0%; Huons Co., Ltd. (243070.KQ), 3.1%; Reyon Pharmaceutical Co., Ltd. (102460.KS), -23.9%; curacle co.,ltd. (365270.KQ), -92.1%.
Has Hyundai Pharmaceutical made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 3.17 billion KRW; FY2022, a loss of 164.58 million KRW; FY2023, 6.12 billion KRW; FY2024, a loss of 574.89 million KRW; FY2025, 2.52 billion KRW. It reported a net loss in 3 of these 5 years.
Data as of .
How to cite: DataPorium, “Hyundai Pharmaceutical Co., Ltd. (004310.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/004310.KS